Opportunity for Leadership in Epigenetic Control of Metastatic Cancer

Sage is representing EpiAxis Therapeutics. We are seeking strategic partners to license their novel technology for epigenetic control of metastatic cancer.

EpiAxis Therapeutics is a leading epigenetics company targeting the nuclear bound lysine-specific demethylase 1 (LSD1) enzyme. The company discovered the dual role that LSD1 plays in reprograming the epigenome in metastatic disease and has novel, best in class inhibitors, against this pivotal target.

EpiAxis’ inhibitors reverse both the epithelial to mesenchymal transition (EMT) of the metastasis initiating cells and, in parallel, redecorate the phenotype of immune T cells to restore and reinvigorate their function in metastatic disease.

Research identifying this target and